Everest Medicines’ Velsipity for UC Receives First Asian Approval in Macau
Everest Medicines (HKG: 1952), a China-based pharmaceutical company, has announced that the regulatory authority in...
Wanbangde Pharmaceutical’s Huperzine A Earns FDA Rare Pediatric Disease Designation for HIE Treatment
China’s Wanbangde New Building Materials Co., Ltd (SHE: 002082) has announced that its subsidiary, Wanbangde...
Andon Health’s Triplex Virus Test Kit Receives US FDA Emergency Use Authorization
Andon Health Co., Ltd (SHE: 002432), a leading healthcare company based in China, has announced...
Citi Pharma Ltd and Hangzhou Newsea Technology Form JV to Boost API Production
Pakistan-based pharmaceutical company Citi Pharma Ltd is entering into a joint venture (JV) agreement with...
Medtronic’s RDN System Symplicity Spyral Earns First-Ever NMPA Approval
Medtronic (NYSE: MDT), the US-Irish medical device giant, has announced that its Symplicity Spyral renal...
Xi and Macron Discuss Enhanced Market Access for Foreign Investors, Focus on Life Sciences
This week, talks between China’s President Xi Jinping and France’s President Emmanuel Macron in France...
LEO Pharma’s Enstilar Outperforms Daivobet in Phase III Psoriasis Trial in China
Denmark-based dermatology specialist LEO Pharma A/S has announced positive outcomes for its drug candidate Enstilar...
Ono Pharmaceutical Secures Deal to Acquire Deciphera Pharmaceuticals for USD 2.4 Billion
Japan-based Ono Pharmaceutical Co., Ltd (TYO: 4528) has announced that it has reached an agreement...
Mabwell Bioscience’s 9MW2821 Earns Orphan Drug Status from FDA for Esophageal Cancer
Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062), a biopharmaceutical company based in China, has announced...
Innovent Biologics’ CLDN18.2 ADC IBI343 Receives Breakthrough Designation in China
Innovent Biologics Inc. (HKG: 1801), a leading biopharmaceutical company based in China, has announced that...
Yantai Dongcheng Pharmaceutical’s Radiopharmaceutical 18F-LNC1007 Cleared for Australian Phase I Trial
Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675), a Chinese pharmaceutical company, has announced that...
Sichuan Biokin’s EGFR/HER3 ADC Expands Phase II Clinical Program with NMPA Approval
Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506), a Chinese biopharmaceutical company, has received approval from...
Bio-Bank Corp. Aims for HKEX IPO with Focus on PDGF Drug Development
B&K Corporation Limited, known as Bio-Bank Corp., has recently filed an initial public offering (IPO)...
China Upgrades Midazolam to Category I Psychotropic Drug List in Regulatory Rescheduling
In a joint notification, the National Medical Products Administration (NMPA), Ministry of Public Security, and...
Merus’s Zenocutuzumab Receives Priority Review Status from FDA for Lung and Pancreatic Cancer Indications
Dutch biotechnology company Merus (NASDAQ: MRUS) has announced that the US Food and Drug Administration...
Lei Haichao Takes Over as Party Secretary of China’s National Health Commission
The National Health Commission (NHC) of China has undergone a leadership change, with Lei Haichao...
Betta Pharmaceuticals Files for Market Approval of CDK4/6 Inhibitor BPI-16350 in China
Betta Pharmaceuticals Co., Ltd (SHE: 300558), a Chinese pharmaceutical company, has announced that it has...
Tonghua Dongbao Pharmaceuticals Commences Phase IIa Trial for Dual-Targeted Gout Drug Candidate
Tonghua Dongbao Pharmaceuticals (SHA: 600867), a China-based pharmaceutical company, has announced that the first patient...
BIO Surveys Members on China-CDMO Dependence Amid BioSecurity Bill Deliberations
The Biotechnology Innovation Organization (BIO), a prominent US industry trade group, is conducting a survey...
Henlius’ HER2 Dual-Targeted Therapy Gets Green Light for Global Phase III Trial by FDA
Shanghai Henlius Biotech Co., Ltd (HKG: 2696) has announced that it has received approval from...